leisure time -WSS

leisure time

author：comprehensive 2025-09-28 01:39:11 - browse：159

Telehealth menopause treatment options displayed on cellphones emerging from a crack in the ground. -- health tech coverage from STAT — Molly Ferguson for STAT

At the turn of the century, nearly 18 million women in the United States were battling hot flashes, night sweats, and other symptoms of menopause with hormones. But in 2002, the therapy went into a free-fall when a landmark trial suggested treating menopause with estrogen and progesterone increased the risk of breast cancer and cardiovascular disease. The study was shut down early — and a year later, prescriptions had plummeted to nearly half what they had been in 2001.

More than two decades later, menopause experts have come to think about the results of the trial very differently. Newer research points to more benefits than risks for many healthy women under 60 treating menopause symptoms with hormone therapy. But many women who are good fits still aren’t getting treatment. “The pendulum has been slowly — too slowly — swinging back,” said OB-GYN Mike Green, chief medical officer of menopause telehealth company Winona.

Winona is part of a new generation of virtual-first health care companies aiming to give that pendulum a push. In the last five years, more than a dozen telehealth companies have started up to serve women in and approaching menopause, including with hormone therapy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Asahi Kasei to buy Calliditas, picking up kidney disease drug

focus

WSS

Guardant Health colon cancer test endorsed by FDA advisory panel

New research sheds light on how often breast cancer is overdiagnosed

How to save PrEP access — and even expand it

Achieving telehealth equity for people with hearing loss

Malaria cases in Florida and Texas: Here’s what you need to know

Cancer drug shortages should be causing more outrage

knowledge

leisure time

knowledge

Walensky prepares to leave CDC — and Congress — behind

United colonoscopy coverage change 'may cost lives,' doctors say

Wildfire smoke exposes gaps in outdoor worker protections

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

As demand for Covid shots wanes, Moderna seeks its next success

Beyond aggravation: Constipation is an American epidemic

BioMarin wins approval for gene therapy to treat hemophilia A

Guidelines to prevent youth baseball injuries need more muscle

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

In age of alternative facts, a scholarly course on calling out crap

Wikipedia

Medical leaders decry Supreme Court decision on affirmative action

Jerome Adams on the need for new antivirals for Covid

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Anesthesiologist group: stop taking Ozempic before surgery

Stroke rates rising, especially in working

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

focus

focus

entertainment

hotspot